Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Hui Yu

Bryan Patrick McKibben

Matt Aaron Tschantz

Derek Cogan

Zhidong Chen

Peter Allen Nemoto

Steven Richard Brunette

Jin Mi Kim

Michael David Lawlor

Eugene R Hickey

Weimin Liu

Neil Moss

Rene Marc Lemieux

Keith R Hornberger

Zhaoming Xiong

Daniel Richard Marshall

Donghong Amy Gao

Lee Fader

Alexander Heim-Riether

Craig Andrew Miller

Xin Guo

Michael Balestra

Simon Surprenant

Joerg Bentzien

René Marc Lemieux

Jennifer Burke

Jennifer A Kowalski

Antonio J M Barbosa

Joshua Courtney Horan

Kenneth Michael Meyers

Yang Yu

Antonio Jose Del Moral Barbosa, Jr

Rene' Marc Lemieux

Joerg Martin Bentzien

Bryan Mckibben

Donghong A Gao

Antonio Jose Del Moral Barbosa

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R, Rand R, are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Aldosterone synthase inhibitors

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

Disclosed are novel compounds of formula (I): wherein X, Y, R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyrimidine derivatives useful as inhibitors of PKC-theta

The invention comprises a class of derivatives of substituted benzylimidazoles of the formula (I) and methods for making the same. These compounds are useful for the treatment of inflammatory conditions. 

Substituted benzylimidazoles useful for the treatment of inflammatory diseases

Growing community of inventors

New Milford, CT, United States of America

Hui Yu